Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Becomes Customer of Third Wave s Drug-Metabolism Assay

NEW YORK, Feb. 12 (GenomeWeb News) - LabCorp has become an "early adopter" of Third Wave Technologies' new Invader cytochrome P450 2D6 assay panel, Third Wave said on Tuesday. It is Third Wave's first pharmacogenomics product.

LabCorp will use the assay, which is classified into four drug-metabolism categories, to help drug makers predict drug response in subjects.

The panel comprises SNPs, single and multiple base-pair deletions, and whole gene deletions and duplications in the 2D6 gene family.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.